100% of patients treated with 150 mg, 300 mg and 600 mg of QX004N achieved PASI 75 at week 12 and PASI ... shown results comparable to risankizumab (Skyrizi, AbbVie), an IL-23a inhibitor indicated ...

FRONTIER 2 included a range of JNJ-2113 doses, with the most effective (100 mg given twice-daily) achieving a 76% PASI 75 response – 78.6% clearance of psoriasis skin lesions – at 52 weeks.

It was better than Stelara in reaching PASI 90 and IGA 0/1 at that timepoint, and also topped placebo on the more stringent PASI 100 and IGA ... s recently-approved Skyrizi (risankizumab ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue forecast of $31 billion for both drugs.

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

The PASI 90 response rate was close to 80%, and the PASI 100 response rate exceeded 40%, all efficacy measures significantly superior to the placebo group. Over 80% of patients achieved a PASI 90 ...

The PASI 90 response rate was close to 80%, and the PASI 100 response rate exceeded 40%, all efficacy measures significantly superior to the placebo group. Over 80% of patients achieved a PASI 90 ...

Rinvoq's total estimated spending came in about $40 million behind Skyrizi's total last year, according to iSpot.TV, while Dupixent's total was about $100 million lower than Skyrizi's. The same ...

Skyrizi and Rinvoq are expected to generate nearly $24 billion in combined sales in 2025, reflecting a $6 billion increase year-over-year. AbbVie raised its 2027 combined sales guidance for these ...

In particular, recently launched drugs Skyrizi and Rinvoq have shown improved efficacy over Humira and other currently leading treatment options, which should support combined annual sales of ...

AbbVie stock retook its 200-day moving average Friday after the company raised its long-term outlook for Skyrizi and Rinvoq by $4 billion.

The decline was offset by sales of its newer arthritis drugs Skyrizi, which soared by 57% to $3.78 billion, and Rinvoq, which logged a 46% gain to $1.83 billion. Chief Executive Robert Michael ...